A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2019-05-28
Target enrollment:
Participant gender:
Summary
This is medical research evaluating the safety and efficacy of two new medicines (necitumumab
and abemaciclib), administered in combination in participants affected by a defined type of
advanced lung cancer (stage IV non-small-cell lung cancer).